Group items tagged

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

NIJ is seeking investigator-initiated proposals to conduct research that examines criminal justice tools, protocols, and policies concerning drug trafficking, markets and use, and the effects of drug legalization and decriminalization on law enforcement, applicable to State, tribal and local jurisdictions. Proposals must address one of two criminal justice activities: drug intelligence and community surveillance, or criminal investigation and prosecution. In addition, NIJ has identified three drug research priorities: Marijuana and cannabis products; Heroin and other opioids (including diverted prescription drugs); and Novel psychoactive substances (also known as synthetic drugs).

NIST is soliciting applications for financial assistance for Fiscal Year 2016 (FY16) within the following NIST Laboratory grant programs: (1) the Material Measurement Laboratory (MML) Grant Program; (2) the Physical Measurement Laboratory (PML) Grant Program; (3) the Engineering Laboratory (EL) Grant Program; (4) the Fire Research (FR) Grant Program; (5) the Information Technology Laboratory (ITL) Grant Program; (6) the Communications Technology Laboratory (CTL) Grant Program; (7) the NIST Center for Neutron Research (NCNR) Grant Program; (8) the Center for Nanoscale Science and Technology (CNST) Grant Program; (9) the Special Programs Office (SPO) Grant Program; (10) the Standards Coordination Office (SCO) Grant Program; (11) the International and Academic Affairs Office (IAAO) Grant Program; and (12) the Associate Director for Laboratory Programs (ADLP) Grant Program.

NIST is soliciting applications for financial assistance for Fiscal Year 2016 (FY16) within the following NIST Laboratory grant programs: (1) the Material Measurement Laboratory (MML) Grant Program; (2) the Physical Measurement Laboratory (PML) Grant Program; (3) the Engineering Laboratory (EL) Grant Program; (4) the Fire Research (FR) Grant Program; (5) the Information Technology Laboratory (ITL) Grant Program; (6) the Communications Technology Laboratory (CTL) Grant Program; (7) the NIST Center for Neutron Research (NCNR) Grant Program; (8) the Center for Nanoscale Science and Technology (CNST) Grant Program; (9) the Special Programs Office (SPO) Grant Program; (10) the Standards Coordination Office (SCO) Grant Program; (11) the International and Academic Affairs Office (IAAO) Grant Program; and (12) the Associate Director for Laboratory Programs (ADLP) Grant Program.

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

This Funding Opportunity Announcement (FOA) issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), builds upon the National Antimicrobial Resistance Monitoring System (NARMS) which was initiated in 1996 as one of the key activities in a national action plan to combat antibiotic resistance threats. The purpose of this FOA is to protect and promote public health by enhancing, strengthening and sustaining antibiotic resistance surveillance in retail food specimens within the NARMS program. The NARMS cooperative agreements will improve the detection of antibiotic resistance among enteric bacteria in food commodities, as well as potentially develop new sites as part of the program. Measurable outcomes of the program will be in alignment with the NARMS Objectives.

The intention of this Funding Opportunity Announcement is to improve the prevention, diagnosis, and treatment of vulvodynia.  By definition, vulvar discomfort or pain without a clear etiology is termed vulvodynia. Some organizations use the term vulvodynia to indicate vulvar pain of unknown etiology for more than 3 months.  For the purposes of this announcement, vulvodynia and vulvar pain will be used interchangeably.  The overall incidence of vulvodynia has been reported as 4.2 cases per 100 person-years in one population based study, with others estimating that persistent vulvar pain affects 9 to 18 percent of women at some point during their lifetime. Current evidence suggests that incidence rates vary by age, ethnicity and marital status.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

The International Research Network Connections (IRNC) program supports high-performance network connectivity required by international science and engineering research and education collaborations involving the NSF research community. NSF expects to make 1-2 awards to link U.S. research networks with peer networks in Europe and Africa and leverage existing international network connectivity. High-performance network connections funded by this program are intended to support science and engineering research and education applications, and preference will be given to solutions that provide the best economy of scale and demonstrate the ability to support the largest communities of interest with the broadest services. Funded projects will assist the U.S. research and education community by enabling state-of-the-art international network services and access to increased collaboration and data services. Through extended international network connections, additional research and production network services will be enabled, complementing those currently offered or planned by domestic research networks.

This Research Announcement (RA) solicits ground-breaking single-investigator proposals from junior faculty for research and development in the areas of physical sciences, engineering, materials, mathematics, biology, computing, informatics, and manufacturing of interest to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO) and Microsystems Technology Office (MTO).

This Research Announcement (RA) solicits ground-breaking single-investigator proposals from junior faculty for research and development in the areas of physical sciences, engineering, materials, mathematics, biology, computing, informatics, and manufacturing of interest to DARPA's Biological Technologies Office (BTO), Defense Sciences Office (DSO) and Microsystems Technology Office (MTO).

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The current pipeline of candidate antimicrobial products is insufficient to counter the threat of antimicrobial resistance . A novel collaborative model is needed to spur innovation and investment towards new antimicrobial products to repopulate the early development pipeline. In 2014, the United States Government released the National Strategy for Combating Antimicrobial Resistant Bacteria. A component of the National Strategy is to establish a Biopharmaceutical Accelerator for Combating Antibiotic-Resistant Bacteria [Accelerator] to fund Research and Development (R&D) activities to help progress candidate products from the proof-of-concept stage through pre-clinical development. Candidates that graduate from the Accelerator will be better positioned for R&D investment and clinical development. There are various Accelerator models in the marketplace. The Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) Accelerator will be a non-equity accelerator that provides non-dilutive funding to product developers for R&D activities and enables the product developers to retain full ownership and control of their company. The Accelerator for CARB will be focusing only on antibacterial products. BARDA will provide direct funding and NIAID will provide in-kind services (e.g. preclinical services, technical expertise) to the Accelerator [the cooperative agreement recipient] that will manage a portfolio of investments of early stage antimicrobial product candidates.

The Chemical Security Program (CSP) partners with government, security, academic, and industrial communities in Africa, the Middle East, and Asia, to strengthen their ability to thwart chemical attacks. CSP accomplishes this aim by sponsoring projects designed to identify and address chemical security vulnerabilities and identify and investigate early warning signs of chemical attacks in preparation.

The Chemical Security Program (CSP) partners with government, security, academic, and industrial communities in Africa, the Middle East, and Asia, to strengthen their ability to thwart chemical attacks. CSP accomplishes this aim by sponsoring projects designed to identify and address chemical security vulnerabilities and identify and investigate early warning signs of chemical attacks in preparation.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The National Science Foundation (NSF) seeks to develop and nurture a national innovation ecosystem that builds upon research to guide the output of scientific discoveries closer to the development of technologies, products and processes that benefit society.

This program will investigate the base of the Selawik River basin aquatic food web, and link it to the anticipated increase in terrestrial inputs of carbon and nitrogen to the aquatic ecosystem as a result of climate change. The main objectives are: 1) assess the quality and quantity of terrestrial dissolved organic carbon (DOC), organic and inorganic nitrogen, and phosphorus released with increased soil thaw depth during spring and early summer, and its entry to the aquatic ecosystem; 2) quantify change in aquatic microbial, mainly bacterial, respiration and production rates with change in DOC quality and quantity; and 3) examine how change in terrestrial DOC and nitrogen inputs to the aquatic ecosystem might alter the rate of phytoplankton primary production, the community composition, and energy (lipid) content.

Cell-based therapies, especially immune cells, have the potential to revolutionize human healthcare in various different contexts, including cancer and personalized medicine. For example, CAR (Chimeric antigen receptor) T-cell therapy for cancer requires modification, in vitro culture and expansion of human T-cells.   Manufacturing of therapeutic cells as the end product presents major engineering challenges.  New therapies and cell-based products depend critically on the development of robust, reliable and reproducible biomanufacturing technologies.

The purpose of this award is to support outstanding basic and/or clinical researchers with the vision and expertise to translate research discoveries into medications for the treatment of Substance Use Disorders (SUDs) stemming from tobacco, cannabis, cocaine, methamphetamine, heroin, or prescription opiate use.Eligible applicants must demonstrate the ability to develop molecules with the potential to treat SUDs and advance them in the drug development continuum. The ultimate goal of this FOA is to bring molecules closer to FDA approval.

Bioequivalence studies that compare a reference formulation to an investigational formulation are typically conducted in healthy adult volunteers and occasionally are conducted in patients. Some populations have unique physical, biological, and physiological considerations that are not reflected by healthy volunteers or by the typical patient for whom a drug is indicated. Physicians have expressed concerns about generic drug substitution (especially for narrow therapeutic index drugs) in special patient populations whose experience with a drug may not be represented by those in whom bioequivalence studies are conducted. For instance, for products that do not have age-appropriate formulations (e.g., formulations do not differ by age of patient), the use of generic products under "off-label" practice patterns in special populations such as crushing or dissolving tablets in liquid for pediatric patients may influence their equivalence to brand name products. Special populations include, but are not limited to, pediatric patients, elderly patients who take multiple medications, women (particularly those who are pregnant), racial/ethnic minorities, and/or individuals with impaired kidney or liver function.

The purpose of this funding opportunity is to support the research and development necessary to advance spectroscopic imaging technologies, methods, study designs, and analyses to non-invasively measure the rate and extent to which a topically applied compound becomes available in the epidermis, at or near a site of action within the skin. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that measures the amount of drug present in the epidermis at each of a series of depths below the skin surface, which can be utilized to monitor epidermal pharmacokinetics by repeated measurements over time.

The Office of Basic Energy Sciences (BES), U.S. Department of Energy (DOE), announces its interest in receiving grant applications from U.S. universities/institutions of higher education for basic research to investigate some of the outstanding scientific questions in the synthesis of ammonia (NH3) from nitrogen (N2) using processes that do not generate greenhouse gases (such as CO2, NOx, etc.). Of interest is molecular level research that will provide the scientific basis for novel catalysts and mechanisms for nitrogen activation. Ideally, this research should produce fundamental knowledge that will lead to future catalytic processes for ammonia synthesis that are energy efficient, use renewable sources of energy, and do not produce greenhouse gases. This FOA will not consider proposals on process or reactor design, optimization or plant-level intensification. Research will not be supported whose primary goal(s) or challenge(s) are hydrogen evolution, oxygen evolution, CO2 capture or conversion, or outside the specific focus on nitrogen activation. See the Summary Criteria section for more information on research areas excluded from this funding opportunity.

Students enrolled in any PhD program are eligible to apply, as are those who earned a PhD in 2016 or 2017. Given candidates with comparative skills and preparation, preference will be given to European-based scholars. To apply, you should submit the following two documents as a SINGLE file, labeled with your last name first (please place "ESEH research grant" in subject line): A 1-2 pages proposal (double-spaced, 12 pt font) explaining your overall project and what specific research activities you will undertake with the funds if granted. You are encouraged to include a budget overview for the specific research activity; where applicable indicate other sources of funding for amounts over EUR 500. A brief curriculum vitae (max. 2 pages) Files in pdf-format are preferred, but Word-compatible formats are also acceptable. Applications will be accepted until 1 December 2018. Notifications will be sent out shortly after the end of this year. Please submit all files to: Marcus Hall, Chair of the ESEH Research Fellowship Committee, researchgrant [at] eseh.org

The American Society for Radiation Oncology is accepting applications for its 2019 Minority Summer Fellowship Award. The annual program is designed to introduce medical students from backgrounds that are underrepresented in medicine to the discipline of radiation oncology early in their medical education. Although medical students in all years are encouraged to apply, preference will be given to first- and second-year students. In an effort to promote radiation oncology as a career choice, the fellowship will expose medical students to clinical, basic, and translational research questions in radiation oncology. The fellowship provides each student with a $4,500 package that includes a $3,500 stipend for the eight-week training program (exceptions can be made for a longer program but will need to be approved by ASTRO's Committee on Health Equity, Diversity and Inclusion, or "CHEDI") and $1,000 toward the cost of travel to the organization's 2019 annual meeting. To be eligible, applicants must be enrolled in a United States medical school and be able to identify a mentor with a successful record of research productivity. The mentor should be an ASTRO member. In addition, research must be undertaken at a North American institution during the summer of 2019.

Sigma Xi, a society of research scientists and engineers that rewards excellence in research and cooperation among scientists in all fields, has been providing undergraduate and graduate students with valuable educational experiences and financial support for more than eighty years. By encouraging close working relationships between students and faculty, the society promotes scientific achievement through hands-on learning. Through the Sigma Xi Grants-in-Aid of Research program, the society awards grants of up to $1,000 to students from all areas of the sciences and engineering. Designated funds from the National Academy of Sciences allow for grants of up to $5,000 for astronomy research and $2,500 for vision-related research. Funding can support travel expenses or nonstandard laboratory equipment necessary to complete a specific research project. While membership in Sigma Xi is not a requirement for applying for funding, approximately 75 percent of Grants-in-Aid of Research funds are restricted for use by dues-paying student members or students whose project advisor is a dues-paying member. Students from any country are eligible to receive funding. Complete program guidelines and application instructions are available on the Sigma Xi Web site.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to lead basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the companion PA-18-395.